Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Genentech
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
Study of the investigational drug MEHD7945A compared to the anticancer drug cetuximab when combined with standard chemotherapy in patients with colorectal cancer without mutation in the KRAS gene (Kras wild type)
1-To evaluate the efficacy, as measured by PFS, of FOLFIRI + MEHD7945A (administered every 2 weeks) versus FOLFIRI + cetuximab (administered weekly) in patients with KRAS wild-type mCRC 2- To eval...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
GENENTECH TDM4373g : Essai de phase 1-2 évaluant la tolérance et l’efficacité d’un traitement associant du trastuzumab et du pertuzumab, chez des patients ayant un cancer du sein localement avancé ou métastatique HER2+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase Ib/II, open-label study of the safety, tolerability, and efficacy of in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanced or metastatic bre...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869g AND ABE4955g IN PATIENTS WITH MILD TO MODERATE ALZHEIMER?S DISEASE ESTUDIO MULTICÉNTRICO, ABIERTO, DE EXTENSIÓN A LARGO PLAZO SOBRE SEGURIDAD DE LOS ESTUDIOS EN FASE II ABE4869g Y ABE4955g EN PACIENTES CON ENFERMEDAD DE ALZHEIMER ENTRE LEVE Y MODERADA
To assess the long-term safety and tolerability of crenezumab administered subcutaneously (SC) every 2 weeks (q2w) or intravenously (IV) every 4 weeks (q4w), in eligible patients with Alzheimer?s dise...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
OAM48619 : Essai de phase 2, randomisé en double aveugle évaluant l’efficacité et la tolérance de l’association de l’onartuzumab, du paclitaxel et du bévacizumab, chez des patientes ayant un cancer du sein triple négatif métastatique. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’association de l’onartuzumab, du paclitaxel (Taxol ®) et du bévacizumab (Avastin®), chez des patientes ayant un cancer du sein t...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A clinical study comparing the effects of chemotherapy plus Avastin to chemotherapy plus Avastin plus a new drug (MEGF0444A) in patients with colorectal cancer that has spread to other parts of the body, who have not received chemotherapy before
To estimate the efficacy of MEGF0444A used in combination with FOLFOX + bevacizumab therapy in patients with previously untreated mCRC, as measured by progression-free survival (PFS)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
Étude GO29779 : étude de phase 1, en escalade de dose, évaluant la tolérance d’une combinaison de deux immunothérapies, GDC0919, un inhibiteur de IDO et l’atezolizumab, un anticorps anti-PD-L1, chez des patients ayant une tumeur solide localement avancée ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
GO29779 : Étude de phase IB, en ouvert, avec escalade de doses visant à évaluer la sécurité et la pharmacologie du GDC-0919 administré avec l'atezolizumab chez des patients atteints de tumeurs solides...
Country
France
organs
Tumeurs solides
Specialty
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Genentech Inc
Update Il y a 4 ans
UN ENSAYO DE FASE II, MULTICÉNTRICO, ALEATORIZADO, DOBLE-CIEGO, CONTROLADO POR PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE GDC-0449 COMO TERAPIA DE MANTENIMIENTO EN PACIENTES CON CÁNCER OVÁRICO EN UNA SEGUNDA O TERCERA REMISIÓN COMPLETA A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN A SECOND OR THIRD COMPLETE REMISSION
El objetivo primario de este estudio es: - Estimar el beneficio clínico de la adición de GDC-0449 como terapia de mantenimiento para pacientes con cáncer ovárico en una segunda o tercera remisión comp...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A clinical trial of MABT5102A for the treatment of Alzheimer's Disease Un ensayo clínico de MABT5102A para el tratamiento de la Enfermedad de Alzheimer
?To evaluate the efficacy of MABT5102A compared with placebo, when administered over 68 weeks to patients with mild to moderate AD, in inhibiting disease progression using the Alzheimer?s Disease Asse...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
To test whether the experimental drug GDC-0449 is safe and effective for advanced basal cell carcinoma
The primary objective of this study is - to estimate the clinical benefit of Vismodegib given as therapy for patients with locally advanced or metastatic BCC, as measured by overall response rate (O...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
Genentech AVF3693g : Essai de phase 3 randomisé, en double aveugle évaluant l’efficacité et la tolérance d’un traitement par bévacizumab associé à une chimiothérapie chez des patients ayant un cancer du sein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase III, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastati...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Previous
1
2
3
4
5
6
7
8
Next